U.S., June 13 -- ClinicalTrials.gov registry received information related to the study (NCT07018518) titled 'PIN in Combination With Anti-PD1 in Previously Treated Primary Hepatocellular Carcinoma' on June 05.
Brief Summary: In this single-center,open-label, phase I study, the safety and efficacy of PIN in combination with programmed cell death protein antibody (anti-PD1) therapeutic regimen will be evaluated in patients with refractory primary advanced hepatocellular carcinoma(HCC) . A total of 25 to 30 patients are planned to be enrolled and receive PIN plus anti-PD1 combined treatment. It aims to: 1).assess the safety and antitumor effects of the above combined treatment regimen. 2).detect the dynamic changes and molecular characteristi...